Cancer patients worldwide are challenged by unmet medical needs every day. We are advancing an innovative solid tumour portfolio, with the aim of discovering additional first-in-class or best-in-class innovative medicines, accessible and affordable for far more patients around the world.
BeiGene’s approach to cancer biology unites cutting-edge research models and processes for drug discovery with the scale of a global organization. We are particularly interested in immuno-oncology, a cornerstone of cancer treatments. There is tremendous potential for synergistic combinations of cancer immunotherapies. Discover our vision in this video from Nils Eckardt, Vice President Medical Affairs, Europe.
Visit BeiGene to learn more:
Learn more about BeiGene’s science and medicines
Explore BeiGene’s medical educational platform for healthcare professionals
BeiGene’s Oncology Pipeline
Pursuing Innovation on 3 Fronts
Immuno-Oncology Agents: Our research and development team focuses on precision targeting of immune checkpoints and other mechanisms of tumour-associated immunity to develop novel drug candidates that synergistically enhance immune cells’ ability to mount a response against cancer cells. In addition, we are working to identify mechanisms by which tumours evade immune systems and target weak points in the cancer immunity cycle.
Molecularly Targeted Agents: The ability to identify specific disease subpopulations through mutations in certain genes and proteins is a critical advancement in oncology, making possible new treatments that are more effective than ever. Rational drug design, in which targets are selected based on their observed role in cancer cell growth and survival, has been a mainstay of our development efforts in specific disease subpopulations from the start.
Combination Solutions: BeiGene is evaluating combination therapies that target distinct steps of anti-tumour immunity, exploring synergies that could result in stronger and more sustained responses.
Learn about clinical-stage development programs in solid tumours and haematology and view mechanism of action videos.
Download the pipeline resource for an overview of BeiGene’s investigational compounds and combinations in our solid tumour oncology and haematology disease areas of interest.
Therapies At A Glance
In this downloadable educational series, learn more about BeiGene therapeutic compounds that target the tumour cellular microenvironment, or the tumour cell itself, through the following mechanisms:
- Anti-PD-1 checkpoint inhibitor
- Anti-TIGIT checkpoint inhibitor
- Anti-OX40 agonist
- Anti-TIM-3 checkpoint inhibitor
- BTK inhibitor
ESMO Industry Sponsored Satellite Symposia
ESMO Congress 2022
Experts: Elizabeth Smyth (United Kingdom), Eric Van Cutsem (Belgium), Michel Ducreux (France), Sylvie Lorenzen (Germany), and Lesley Fallowfield (United Kingdom)
ESMO Congress 2021
Experts: Heather A. Wakelee (USA), Benjamin Besse (France), Stephen V. Liu (USA), Riyaz Shah (United Kingdom), and Ross Soo (Singapore)
ESMO Virtual Congress 2020
Experts: Tony Mok (Hong Kong), Giorgio Scagliotti (Italy), Anne-Marie C. Dingemans (Netherlands), and Raffaele Califano (United Kingdom)
ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.